Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.

NCT05305573 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19
SARS-CoV-2 Acute Respiratory Disease

Interventions

BIOLOGICAL: COVID-19 Vaccine HIPRA 40 ug/dose
BIOLOGICAL: Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection

Sponsor

Hipra Scientific, S.L.U